Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951340 · ClinicalTrials.gov registry record · Phase 1
Desensitization and Cognitive Therapy in General Anxiety.
A Phase 1 study, sponsored by Penn State University.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT00951340: Completed Phase 1 study, sponsored by Penn State University.
NCT00951340 is a Phase 1 study that has completed, run by Penn State University. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00951340, a Phase 1 study, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study will test the feasibility and safety of adding interpersonal and emotional processing techniques to standard cognitive behavioral therapy for generalized anxiety disorder.
Interventions
- OTHER Cognitive behavioral therapy (CBT)
- BEHAVIORAL Emotional processing and interpersonal therapy
- BEHAVIORAL Listening therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 1996-07 |
| Est. Completion | 1998-12 |
| Phase | Phase 1 |
What the finished NCT00951340 record still lists
NCT00951340 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 3 interventions - of which Cognitive behavioral therapy (CBT) is the first listed.
NCT00951340 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00951340 about?
NCT00951340 is a clinical study titled "Desensitization and Cognitive Therapy in General Anxiety.". This study will test the feasibility and safety of adding interpersonal and emotional processing techniques to standard cognitive behavioral therapy for generalized anxiety disorder.
What is the current status of trial NCT00951340?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 1996-07. Estimated completion is 1998-12.
What interventions are being tested in trial NCT00951340?
The interventions under investigation include: Cognitive behavioral therapy (CBT) (OTHER), Emotional processing and interpersonal therapy (BEHAVIORAL), Listening therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT00951340?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00951340's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia